




RealRate

PHARMACEUTICAL 2017

Viking Therapeutics Inc.
Rank 206 of 292





PHARMACEUTICAL 2017

Viking Therapeutics Inc.
Rank 206 of 292

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Viking Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is -8.5%, being 11% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	13,975
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,477
Liabilities, Non-Current	16
Other Assets	561
Other Compr. Net Income	0.48
Other Expenses	0
Other Liabilities	0
Other Net Income	-885
Other Revenues	0
Property and Equipment	0
Research and Development	9,000
Selling, General and Administrative Expense	4,847

Output Variable	Value in 1000 USD
Assets	14,536
Liabilities	6,493
Expenses	13,847
Revenues	0
Stockholders Equity	8,043
Net Income	-14,732
Comprehensive Net Income	-14,732
Economic Capital Ratio	-8.5%